Realizing the full potential of ADCs by unlocking new classes of payloads

Firefly Bio

Firefly is excited to share that we've closed a $94M Series A to advance Degrader Antibody Conjugates (DACs) that combine the unique strengths of ADCs with selective protein degraders. We're funded by Versant Ventures, MPM BioImpact, Decheng Capital, and Eli Lilly & Co. 
https://lnkd.in/grEAF9U8

Firefly Bio is a biotechnology company focused on developing new classes of payloads for Antibody-Drug Conjugates (ADCs) with the help of renowned researchers with decades of experience in ADC discovery and development.

COM:FIREFLYBIOLOGICS

Firefly Bio

Filings Not Available